Jeff Hansen

Jeff Hansen

| This email address is being protected from spambots. You need JavaScript enabled to view it.

Research Editor

jeffhans@uab.edu • (205) 209-2355

Communicates UAB research discoveries and initiatives from across the university for a variety of audiences.

Specific beats include: biochemistry; cell, developmental and integrated biology; microbiology; molecular genetics; neurobiology; pathology; pharmacology and tocixology; Alabama Drug Discovery Alliance; Bill L. Harbert Institute for Innovation and Entrepreneurship.

The 31 new scholars from 22 U.S. institutions are all outstanding early career faculty in science who have the potential to become leaders in their research fields and advance diversity, equity and inclusion. Each scholar will receive up to $8.6 million over 10 years.
Knowledge of this previously unrecognized mechanism may aid therapy for patients with interleukin-6 signaling mutations and hyper-IgE Syndrome, or HIES.
Uncovering a pathophysiological mechanism that initiates, transitions and sustains neuropathic pain holds promise for treating neuropathic pain.
Description of this mechanism offers a promising therapeutic target to limit lung injury and death. Lower respiratory tract infections, including bacterial pneumonia, are the fourth-leading cause of death worldwide, with 120 million to 156 million cases and 1.4 million deaths a year.
This is the first example of a chelator-free-radiolabeled polymersome capable of a long-term multiday positron emission tomography, or PET, imaging study in vivo.
Researchers identify a new target to fight infections caused by the opportunistic lung pathogen Streptococcus pneumoniae — interference with the bacteria’s fermentation metabolism.
These effector memory B cells appear poised for a rapid serum antibody response upon secondary challenge one year later, and evidence shows that the cells in this subset differ from all previously described memory B cell subsets.
The grant validates the science of Alveolus Bio, and the funds will support development of first-of-its-kind inhaled biotherapeutics to treat chronic lung diseases.
The federal mandate, which was announced in 2011 and implemented in 2014, limited acetaminophen to 325 milligrams per opioid-acetaminophen combination pill. Acetaminophen is toxic to livers at high doses.
Mechanistic findings in this study may pave the way for future time-restricted feeding studies in muscle, providing a natural and affordable form of alternative therapy for managing pathologies related to metabolism and obesity.
Page 4 of 49